Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reissue Patent
2000-06-21
2002-06-11
Graser, Jennifer E. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S184100, C424S185100, C424S831000, C530S350000, C530S412000, C530S807000
Reissue Patent
active
RE037741
ABSTRACT:
This is a reissue of U.S. Pat. No.
5
,
770
,
213
issued on Jun.
23
,
1998
from application Ser. No.
08
/
210
,
394
filed on May
5
,
1994
.
FIELD OF INVENTION
The present invention relates to P5 outer membrane protein of the Haemophilus influenzae bacterial strain and antibodies directed to P5 protein. The invention also relates to a method of isolating P5 protein and a vaccine composition for use in the treatment of Haemophilus influenzae infection.
BACKGROUND OF INVENTION
Haemophilus influenzae strains are divided into two groups, typable and nontypable. Strains which possess a known capsule are typed by a serological reaction of the capsule with reference antisera. Currently, types a-f have been identified as typable. Strains which do not possess a capsule and fail to react with any of the reference antisera are nontypable.
Nontypable Haemophilus influenzae (NTHI) infections are implicated in several disease states including otitis media, sinusitis, and chronic pulmonary obstructive disease. Haemophilus influenzae type b (Hib) is a major cause of meningitis and other invasive infections in children under the age of four years. Antibodies directed against the capsular polysaccharide of the organism are bactericidal, opsonic in vitro and protective in experimental animals and humans. As used herein, opsonic is defined as preparation of the surface of microorganisms so that they can be more readily taken-up by phagocytes. While safe and effective vaccines for the prevention of Haemophilus influenzae type B disease have been produced, the vaccines are all based on producing antibodies to the polysaccharide capsule which is exterior to the cell wall in the bacteria. NTHi strains of Haemophilus influenzae strains by definition lack a capsule. Therefore, antibodies to capsule will not be effective at preventing NTHi infections.
It is of interest to characterize outer membrane proteins of Haemophilus influenzae bacteria and assess their vaccine potential. Munson et al., (J. Clin. Invest, 72:677-684 (1983)) reported the purification and characterization of P2, one of the major outer membrane proteins of Haemophilus influenzae strains. The researchers found that P2 protein is present in high concentrations, is easily purified, and induces protective antibody in rabbits. P5 protein is thought to be associated with the outer membrane protein layer and was previously extracted by solubilization with sodium dedecyl sulfate (SDS) and organic solvent fractionation. (Coulton et al. Can. J. Microbiology. 20:280-287 (1983)). It has been suggested, however, that the use of SDS may denature proteins in certain circumstances.
Munson and Granoff (American Society of Microbiology (p. 544. (1985)), have reported the partial characterization of P5 and P6 proteins. The results indicated that while P6 cell wall complex elicited antibody in rabbits which had protective activity in the infant rat model, P5 did not yield antiserum which was protective in
infants
infant
rats nor did
it atisera revert wth
its antisera react with
surface of bacteria by immunofluorescence which had immunofluorescence activity in vitro. Based on these findings those skilled in the art concluded that P5 was not a vaccine candidate for the prevention of disease caused by Haemophilus influenzae type b.
SUMMARY OF THE INVENTION
It is an object of the present invention, therefore, to provide essentially pure P5 outer membrane protein of Haemophilus influenzae bacteria, antibodies directed to P5 protein and a vaccine composition for use in the treatment of Haemophilus influenzae infective strains.
It is a further object of the present invention to provide a method of purifying P5 protein from the outer membrane of Haemophilus influenzae bacteria and which yields protein which can be used to produce active antibodies. Thus, P5 can be used to produce a vaccine for NTHi and type b strains of Haemophilus influenzae. The invention may be more fully understood by reference to the following drawings and detailed description.
REFERENCES:
patent: 5098997 (1992-03-01), Anilionis et al.
patent: 5766608 (1998-06-01), Kolattukudy et al.
Purification and Partial Characterization of Outer Membrane Proteins P5 and P6 from Haemophilus Influenzae Type b. American Society for Microbiology, R. Munson, Jr. and D. Granoff, May 1985.*
Spinola, S. M., et al., The Major Outer Membrane Protein of Haemophilus ducreyi Is a Member of the OmpA Family of Proteins, Infection and Immunity, Apr. 1993, pp. 1346-1351.*
Faden, H., et al., Otitis Media in Children. I. The Systemic Immune Response to Nontypable Haemophilus influenzae, 1989, The Journal of Infectious Diseases, vol. 160, No. 6, pp. 999-1004.*
Munson et al., Infection & Immunity 61:4017-4020, Sep. 1993.
Hughes et al., ABSTRACTS of the 92nd General Meeting of the American Society for Microbiology, p. 106, Abstr. D-63, 1992.
Munson et al., Infection & Immunity 49:544-549, 1985.
Green et al., Infection & Immunity 61:1950-1957, 1993.
Houghten et al., VACCINES, 86 New Approaches to Immunization, pp. 21-25, 1986.
Munson, Jr. et al., ABSTRACTS of the 24th Interscience Conference on Antimicrobial Agents & Chemotherapy, held in Washington, D.C. on Oct. 8-10, 1984, p. 234, Abstr. No. 829.
Spinola et al., Infection & Immunity 61:1346-1351, Apr. 1993.
Faden et al., Journal of Infection Diseases 160(6):999-1004, 1989.
Loeb et al., Infection & Immunity 55:2612-2618, 1987.
L. van Alphen et al., Infection & Immunity 56:1800-1806, 1988.
T. Sirakova et al., Infection & Immunity 62:2002-2020, 1994.
American Cyanamid Company
Gordon Alan M.
Graser Jennifer E.
Rosenblum Anne M.
LandOfFree
Purified nontypable Haemophilus influenzae P5 protein as a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purified nontypable Haemophilus influenzae P5 protein as a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purified nontypable Haemophilus influenzae P5 protein as a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2902073